First published in The Lancet on 2019 Jul 13.Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Authors: Gerstein HC, Colhoun HM, Dagenais...Read Article
This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
First published in John Wiley & Sons Ltd., Diabetes obesity and metabolism on 2017 Apr.Diabetes Obes Metab. 2017 Apr;19(4):489-495. doi:...Read Article